ZYNERBA PHARMACEUTICALS, INC.: 10-Q filed 2015-11-12

Name: ZYNERBA PHARMACEUTICALS, INC.: 10-Q filed 2015-11-12
Creator: ZYNERBA PHARMACEUTICALS, INC.

What ZYNERBA PHARMACEUTICALS, INC. reported in its quarterly report filed 2015-11-12 (fiscal Q3 2015): 28 published measures, 72 facts as tagged in accession 0001558370-15-002642.

This filing

Form: 10-Q (quarterly report)
Filed: 2015-11-12
Fiscal period: fiscal Q3 2015
Accession: 0001558370-15-002642 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ZYNERBA PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2015-09-30	47,095,112	USD
At 2014-12-31	11,616,671	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2015-09-30	44,381,384	USD
At 2014-12-31	-8,051,675	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2015-09-30	44,806,731	USD
At 2014-12-31	9,330,681	USD
At 2014-09-30	4,363,874	USD
At 2013-12-31	154,695	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-3,993,744	USD	92
2015-01-01 to 2015-09-30	-7,112,089	USD	273
2014-07-01 to 2014-09-30	-2,515,246	USD	92
2014-01-01 to 2014-09-30	-4,265,260	USD	273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	-6,592,668	USD	273
2014-01-01 to 2014-09-30	-2,074,425	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	176,096	USD	273
2014-01-01 to 2014-09-30	15,392	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	42,244,814	USD	273
2014-01-01 to 2014-09-30	6,298,996	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	-176,096	USD	273
2014-01-01 to 2014-09-30	-15,392	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2015-09-30	-17,140,794	USD
At 2014-12-31	-10,028,705	USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2015-09-30	229,012	USD
At 2014-12-31	19,642	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-3,995,316	USD	92
2015-01-01 to 2015-09-30	-7,115,037	USD	273
2014-07-01 to 2014-09-30	-2,514,887	USD	92
2014-01-01 to 2014-09-30	-4,263,416	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2015-09-30	46,865,900	USD
At 2014-12-31	11,594,829	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2015-09-30	2,713,728	USD
At 2014-12-31	3,145,535	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2015-09-30	615,530	USD
At 2014-12-31	313,937	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	4,194,723	USD	92
2015-01-01 to 2015-09-30	7,344,662	USD	273
2014-07-01 to 2014-09-30	3,040,358	USD	92
2014-01-01 to 2014-09-30	4,999,271	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	2,271,968	USD	92
2015-01-01 to 2015-09-30	4,136,659	USD	273
2014-07-01 to 2014-09-30	932,838	USD	92
2014-01-01 to 2014-09-30	1,585,711	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2015-09-30	9,199,920	shares
At 2014-12-31	2,029,747	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2015-09-30	61,512,978	USD
At 2014-12-31	1,975,000	USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Period	Value	Unit	Days
At 2015-09-30	245,387	USD
At 2014-12-31	23,245	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2015-09-30	16,375	USD
At 2014-12-31	3,603	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2015-09-30	200	USD
At 2014-12-31	2,200	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2015-09-30	1,207,698	USD
At 2014-12-31	1,711,473	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2015-09-30	2,059,169	USD
At 2014-12-31	1,183,949	USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-3,993,744	USD	92
2015-01-01 to 2015-09-30	-7,112,089	USD	273
2014-07-01 to 2014-09-30	-2,515,246	USD	92
2014-01-01 to 2014-09-30	-4,353,214	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	1,922,755	USD	92
2015-01-01 to 2015-09-30	3,208,003	USD	273
2014-07-01 to 2014-09-30	2,107,520	USD	92
2014-01-01 to 2014-09-30	3,413,560	USD	273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	8,230	USD	92
2015-01-01 to 2015-09-30	12,772	USD	273
2014-07-01 to 2014-09-30	6,850	USD	92
2014-01-01 to 2014-09-30	25,612	USD	273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	42,181,305	USD	273
2014-01-01 to 2014-09-30	1,409	USD	273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	1,289,307	USD	273
2014-01-01 to 2014-09-30	413,264	USD	273

Inspect the source

Entity: ZYNERBA PHARMACEUTICALS, INC. / CIK 0001621443
Captured: 2026-09-22 19:53 UTC
SEC response SHA-256: eb291da6063ca15bb79701a29894e4fddd9d66bcb1e18e0733be9f2efb07eaa3

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001621443.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))